The present invention relates generally to systems and methods for heat exchange with a patient's airways and lungs for selective modification and control of a patient's body temperature. More particularly, it relates to a system and a method for controlling a patient's core body temperature by introducing frozen particles into the patient's respiratory system while monitoring exhalation temperature.
Normal functioning of the human animal requires a body temperature of approximately 37 degrees Celsius (98.6 degrees Fahrenheit). The body can self-compensate for small upward or downward variations in temperature through the activation of a built-in thermoregulatory system, controlled by temperature sensors in the skin. The response to an upward variation in body temperature is the initiation of perspiration, which moves moisture from body tissues to the body surface. When the moisture reaches the surface it evaporates, carrying with it a quantity of heat. The response to a downward variation in body temperature is shivering, which is the body's attempt to generate heat. Shivering is an involuntary contraction and expansion of muscle tissue occurring on a large scale. This muscle action creates heat through friction.
Hypothermia is defined as a core temperature of less than 35° C. and is considered a clinical state of subnormal temperature when the body is unable to generate sufficient heat to effectively maintain functions. Many variables contribute to the development of hypothermia. Age, health, nutrition, body size, exhaustion, exposure, duration of exposure, wind, temperature, wetness, medication and intoxicants may decrease heat production, increase heat loss, or interfere with thermostability. The healthy individual's compensatory responses to heat loss via conduction, convection, radiation, evaporation and respiration may be overwhelmed by exposure. Medications may interfere with thermoregulation. Acute or chronic central nervous system processes may decrease the effectiveness of thermoregulation.
Recent medical reports have described the use of controlled hypothermia as a means to reduce oxygen consumption of tissue, such as the heart muscle and the brain during decreased perfusion that occurs as a result of myocardial infarction and ischemic stroke (respectively), which leads to reduced damage and decrease of the infarcted area. Medical reports have also described the prophylactic use of controlled hypothermia during cardiac surgery or interventional cardiology procedures for reducing damage from ischemia and/or embolization in the heart and brain during and after the procedure.
U.S. Pat. Nos. 8,100,123; 8,281,786; 8,402,968; and U.S. Patent Publ. No. 2013/0085554, all commonly assigned with the present application and incorporated herein by reference, describe improved systems and methods for inducing hypothermia in patients by introducing ice or other frozen particles into the lungs or other body cavities of the patient. As the frozen particles melt, heat is absorbed by the heat (enthalpy) of melting, and the body of the patient is cooled. While offering considerable advantages of prior systems for inducing hypothermia, the respiratory introduction of ice and other frozen particles can be difficult to control and has the potential to cool a patient beyond any desired therapeutic range.
For those reasons, it would be desirable to provide methods and systems for inducing hypothermia with a reduced risk of overcooling the patient. Such methods and systems should further provide for rapid attainment of a desired core body temperature and subsequent maintenance of the core temperature with minimum deviation. At least some of these objections will be met by the inventions described below.
U.S. Pat. Nos. 8,100,123; 8,281,786; 8,402,968; and U.S. Patent Publ. No. 2013/0085554 have been described above. U.S. Patent Publ. 2013/0226077 describes monitoring exhalation temperature in a peritoneal hypothermia system that optionally delivers phase change fluids to the peritoneal cavity.
In a first aspect, the present invention provides a method for lowering a core body temperature of a patient. The method comprises delivering a breathing gas to a respiratory system of the patient during a series of inhalation cycles. The respiratory system includes the lungs, the trachea, the nasal sinuses and nasal passages. In addition to the breathing gas, frozen particles are also delivered to the respiratory system during at least a portion of some of the inhalation cycles. The particles are usually ice, comprising mostly or entirely water or saline, but could also be frozen carbon dioxide or other non-toxic materials which can melt or sublimate to absorb body heat as a result of an enthalpy of melting or sublimation. The temperature of exhaled gases is measured during at least some exhalation cycles, and the amount of frozen particles delivered to the patient can be adjusted in order to achieve a target core temperature based on the measured temperature of the exhalation gases.
The breathing gas and the frozen particles can be delivered in a variety of ways including using a breathing mask as taught in U.S. Pat. Nos. 8,100,123; 8,281,786; and 8,402,968, the full disclosures of which are incorporated herein by reference. In other embodiments, the breathing gas and/or the frozen particles may be delivered through an endotracheal tube. The breathing gas and the frozen particles can be delivered through the same conduits or through separate conduits, and the frozen particles can be generated externally of the delivery system and/or in situ within the delivery system.
Adjusting the amount of frozen particles being delivered (which determines the cooling capacity of the system) may comprise adjusting a duration and/or a rate of the frozen particle delivery during individual inhalations. The method will typically comprise at least an initial phase wherein a sufficient amount of the frozen particles is delivered to rapidly lower the core body temperature to a target core temperature, generally in a target range from 33° C. to 35° C., and a maintenance phase wherein a lesser amount of frozen particles and/or other cooling media is delivered to maintain the target core temperature in the desired target range without lowering the patient's core temperature beyond a desired lower threshold.
In a second aspect, the present invention provides a system for lowering a core body temperature of a patient. The system comprises at least one conduit configured to deliver a an amount of frozen particles (typically together with a breathing gas) to the patient's respiratory system. A temperature sensor is configured to measure a temperature of gas being exhaled through the at least one conduit, and a controller is configured to display exhalation temperature and optionally to adjust the amount, duration and/or rate of delivery of frozen particles through the at least one conduit. Using the system, a target core temperature of the patient can be achieved and maintained by manually and/or automatically adjusting the amount or rate of frozen particles delivered to the respiratory system of the patient.
In specific embodiments, the system includes one conduit for delivering the breathing gas and a separate conduit for delivering the frozen particles, where the one breathing gas conduit usually also provides an exhalation path. In particular embodiments, the conduit may comprise a breathing mask or an endotracheal and/or intranasal tube.
The controller may be configured to automatically control the delivery amount or rate of frozen particles in response to the exhalation temperature measured by the temperature sensor according to a feedback algorithm. In other embodiments, the controller may be configured to allow a user to manually control the delivery amount or rate of frozen particles in response to the exhalation temperature measured by the temperature sensor.
The system may optionally include an audible or visual alarm configured to detect any one of a variety of abnormal conditions, particularly including a reduction in the exhalation and/or the body core temperature below a lower safety threshold. Conveniently, the exhalation temperature sensor can be used for that function as well as for control. Other sensors that measure lung fluid (such as thoracic impedance sensors), humidity sensors in the breathing tube that measure the presence of fluid in the exhaled air, protein detectors that measure the present of proteins in the exhalation tube (protein as a marker for pulmonary edema), blood sensors for detecting the presence of blood in the fluid in the exhalation tube (another marker of pulmonary edema), and the like. The system may also provide for the automatic reduction or cessation of frozen particle deliver to the lungs whenever an alarm condition is detected.
The invention will be described, by way of example, and with reference to the accompanying diagrammatic drawings, in which:
The methods and systems of the present invention induce hypothermia in a patient by introducing ice or other non-toxic, biologically compatible frozen particles into a patient's lungs or other regions of the respiratory system. Melting or sublimation of the frozen particles provides a high rate of enthalpic heat absorption which rapidly cools the lungs and other regions of the respiratory tract, thus cooling the blood in the lungs which in turn flows to cool the heart and brain as well as the body core and extremities as cooled blood is circulated through the patient.
The present invention provides methods for monitoring the patient's core body temperature, particularly including the temperature of the lungs and heart, by measuring the temperature of the patient's exhalation to provide a real time profile of the body core temperature. The temperature of the exhaled air is measured during at least a portion of at least some of the exhalation cycles and the temperature profile, typically being measured during the entire duration of each exhalation cycle in order to determine a lowest exhaled air temperature (during that exhalation cycle) which is recorded and stored. The temperature of the exhaled air, and in particular the lowest temperature of the air exhaled in any exhalation cycle, closely correlates with the body core temperature, optionally after a calibration phase, particularly with the lung and heart temperatures at the time of exhalation. Such accurate, real time body core temperature measurement allows for control of the body core temperature, for example by controlling the amount of frozen particles which are delivered to the patient's respiratory at any given time.
The system may optionally include an automatic controller or other programmable component which allows control of the body core temperature based upon the measured exhalation temperature using conventional control algorithms, such as proportional control, derivative control, combinations of proportional and derivative control, as well as feed forward control algorithms which rely on modeling the heat transfer and other characteristics which are related to the correlation between exhaled air temperature and body core temperature. The algorithm can optionally generate an alarm when a temperature exceeds or falls lower than the pre-determined target range. Alternatively, the control can be done manually where a physician or other user is able to adjust the amount or rate of the delivery of ice particles to the patient to achieve rapid cooling to a target core temperature.
Once the target core temperature is reached, the methods of the systems of the present invention will further allow for maintenance of that temperature. For example, the system or doctor may reduce the amount of frozen particles being delivered to the patient to an amount sufficient to maintain but not further lower the body core temperature. Alternatively, other cooling fluids may be utilized in addition to or in place of the frozen particles. Still further alternatively, the use of cooling jackets and other patient cooling apparatus may be used in place of or in addition to the respiratory cooling systems once the target core temperature has been reached.
The system may also include sensors to detect early signs of pulmonary edema or lungs fluid overload which will enable lowering the ice amount being delivered. The controller could also be connected to receive data from the ventilator data and be programed to automatically or manually (by alarming) reduce the ice dose if the ventilator show signs of increased lung resistance to the ventilation.
Referring now to
A controller 22 is connected to a temperature sensor 24 present in an output line or port 26 which carries the exhaled breath from the patient. The temperature sensor, of course, may be disposed within the breathing mask and preferably will be as close to the patient's mouth M as possible in order to measure the exhaled gas temperature as accurately as possible. The controller 22 will measure the temperature from the sensor 24 and will typically include an output display which is visible to the user. The user may thus manually control the control valve 18 in order to adjust the flow of the frozen particles or the timing of the flow. In other embodiments, however, the controller 22 will provide a control signal via line 30 to the valve 18 in order to automatically control the valve, including both on-off control as well as proportional control, integral control, proportional-integral control and other conventional or unconventional control algorithms.
The system may optionally have the ability to synchronize the frozen particle delivery to a specific phase of breathing, preferably the inhalation phase or cycle or a specific portion of the inhalation phase or cycle. The breathing phase and stage could be tracked using an exhaled gas sensor and/or a sensor on the patient's chest or other part of the patient's upper body that will send chest expansion which represents inhalation and chest volume reduction as part of exhalation. In addition to the mask, the system may include an additional tube which will be in continuation with the frozen particle delivery tube and potentially also of the breathing air tube. This extension tube will be positioned deeper in the pharynx but still external to the vocal cords. The purpose is to reduce the heat exposure of the ice to the buccal membrane and the rest of the mouth.
A second exemplary system 40 constructed in accordance with the principles of the present invention is illustrated in
After the patient P has been intubated with the conduit(s) or endotracheal tube 42, breathing air will be provided in a conventional manner from a breathing source 54. In addition, frozen particles will be delivered from a source of frozen particles 56 through a valve 58. A controller 62 senses the temperature of the patient's exhalation through a temperature sensor 64 connected to the controller by line 66. The temperature sensor 64 is located at an outlet of the conduit or endotracheal tube 42. It will be appreciated that the sensor could be located nearer a distal end of the conduit or endotracheal tube so that the temperature being measured is closer to the lungs. As with the first system, the temperature measured by the sensor 64 will typically be displayed on the controller 62 allowing a physician or other user to manually adjust the delivery of the ice particles in order to control the patient's core body temperature. Alternatively, valve 58 may be controlled via a signal line 70 which receives an automatic control signal from the controller 62 as described above with reference to the first system. The system may include other sensors, as described above, to indicate increased fluid in the lungs and/or increased ventilation pressure, and the data from those sensors may optionally be delivered to the controller to automatically reduce an amount of frozen particles delivered if needed.
Referring now to
Usually, the ice will be delivered during only a portion of the inhalation cycle. For example, as shown in a second graph from the top of
While use of the puffs is desirable since it helps prevent clogging of the ice delivery components of the system it is not necessary. The frozen particles may be delivered in a single spike 86 where the amount of frozen particles in the spike may be varied by controlling either the duration or the rate of the spike as shown in solid line and broken line, respectively. Similarly, the burst need not be in the form of a square wave but could also have a time-varying profile 90 as shown at the bottom of
This application is a continuation of U.S. patent application Ser. No. 14/479,128, filed Sep. 5, 2014, which claims the benefit of U.S. Provisional Application Ser. No. 61/875,093, filed Sep. 8, 2013, the entire content of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2687623 | Aubrey | Aug 1954 | A |
4046139 | Horn et al. | Sep 1977 | A |
4711375 | Maeder et al. | Dec 1987 | A |
5035750 | Tada et al. | Jul 1991 | A |
5203794 | Stratford et al. | Apr 1993 | A |
5474533 | Ward et al. | Dec 1995 | A |
5755756 | Freedman, Jr. et al. | May 1998 | A |
5964217 | Christopher | Oct 1999 | A |
6014972 | Sladek | Jan 2000 | A |
6089229 | Bathe | Jul 2000 | A |
6149624 | McShane | Nov 2000 | A |
6244052 | Kasza | Jun 2001 | B1 |
6303156 | Ferrigno | Oct 2001 | B1 |
6306119 | Weber et al. | Oct 2001 | B1 |
6547811 | Becker et al. | Apr 2003 | B1 |
6555057 | Barbut et al. | Apr 2003 | B1 |
6572638 | Dae et al. | Jun 2003 | B1 |
6582457 | Dae et al. | Jun 2003 | B2 |
6585752 | Dobak et al. | Jul 2003 | B2 |
6669661 | Yee | Dec 2003 | B1 |
6736790 | Barbut et al. | May 2004 | B2 |
6962601 | Becker et al. | Nov 2005 | B2 |
6983749 | Kumar et al. | Jan 2006 | B2 |
7070612 | Collins et al. | Jul 2006 | B1 |
7422601 | Becker et al. | Sep 2008 | B2 |
7892269 | Collins et al. | Feb 2011 | B2 |
8100123 | Belson | Jan 2012 | B2 |
8281786 | Belson | Oct 2012 | B2 |
8308787 | Kreck | Nov 2012 | B2 |
8402968 | Belson | Mar 2013 | B2 |
8465535 | Harris et al. | Jun 2013 | B2 |
9004066 | Belson | Apr 2015 | B2 |
9320644 | Kreck et al. | Apr 2016 | B2 |
9414959 | Belson et al. | Aug 2016 | B2 |
9522080 | Collins et al. | Dec 2016 | B2 |
9757272 | Belson et al. | Sep 2017 | B2 |
10238831 | Belson | Mar 2019 | B2 |
10893976 | Belson | Jan 2021 | B2 |
11020269 | Mirizzi | Jun 2021 | B2 |
20020023640 | Nightengale | Feb 2002 | A1 |
20030024530 | Sniadach | Feb 2003 | A1 |
20030056789 | Takano et al. | Mar 2003 | A1 |
20030066304 | Becker et al. | Apr 2003 | A1 |
20030131844 | Kumar et al. | Jul 2003 | A1 |
20030136402 | Jiang et al. | Jul 2003 | A1 |
20030152500 | Dalziel et al. | Aug 2003 | A1 |
20040064171 | Briscoe et al. | Apr 2004 | A1 |
20040092920 | Rozenshpeer | May 2004 | A1 |
20040138608 | Barbut et al. | Jul 2004 | A1 |
20040158303 | Lennox et al. | Aug 2004 | A1 |
20040210281 | Dzeng et al. | Oct 2004 | A1 |
20040261438 | Clulow et al. | Dec 2004 | A1 |
20050042170 | Jiang et al. | Feb 2005 | A1 |
20050177212 | Njemanze et al. | Aug 2005 | A1 |
20050279108 | Akselband et al. | Dec 2005 | A1 |
20060036302 | Kasza et al. | Feb 2006 | A1 |
20060190066 | Worthen | Aug 2006 | A1 |
20060276552 | Barbut et al. | Dec 2006 | A1 |
20070123813 | Barbut et al. | May 2007 | A1 |
20080015543 | Wang | Jan 2008 | A1 |
20080262377 | Belson | Oct 2008 | A1 |
20090076573 | Burnett et al. | Mar 2009 | A1 |
20090107491 | Belson | Apr 2009 | A1 |
20090125087 | Becker et al. | May 2009 | A1 |
20090192505 | Askew et al. | Jul 2009 | A1 |
20100324635 | Kreck | Dec 2010 | A1 |
20110005522 | Vervoort | Jan 2011 | A1 |
20120031405 | Geist | Feb 2012 | A1 |
20120080031 | Belson | Apr 2012 | A1 |
20120167878 | Belson | Jul 2012 | A1 |
20120310312 | Yee | Dec 2012 | A1 |
20130000642 | Fearnot et al. | Jan 2013 | A1 |
20130085554 | Belson et al. | Apr 2013 | A1 |
20130116761 | Kreck | May 2013 | A1 |
20130204331 | Harikrishna et al. | Aug 2013 | A1 |
20130226077 | Burnett et al. | Aug 2013 | A1 |
20140060534 | Belson | Mar 2014 | A1 |
20140350648 | Ericson | Nov 2014 | A1 |
20150151073 | Shushunov | Jun 2015 | A1 |
20150351955 | Belson | Dec 2015 | A1 |
20160175141 | Wu et al. | Jun 2016 | A1 |
20160296365 | Kreck et al. | Oct 2016 | A1 |
20160324685 | Belson | Nov 2016 | A1 |
20170049618 | Ward et al. | Feb 2017 | A1 |
20170112662 | Collins et al. | Apr 2017 | A1 |
20170266037 | Belson | Sep 2017 | A1 |
20180153739 | Mirizzi et al. | Jun 2018 | A1 |
20210137731 | Mirizzi | May 2021 | A1 |
Number | Date | Country |
---|---|---|
102271741 | Dec 2011 | CN |
29909141 | Sep 1999 | DE |
102007019616 | Oct 2008 | DE |
0206982 | Dec 1986 | EP |
H01203700 | Aug 1989 | JP |
2003505190 | Feb 2003 | JP |
2007518544 | Jul 2007 | JP |
WO-9966938 | Dec 1999 | WO |
WO-0018459 | Apr 2000 | WO |
WO-0108593 | Feb 2001 | WO |
WO-0109558 | Feb 2001 | WO |
WO-02085417 | Oct 2002 | WO |
WO-03047603 | Jun 2003 | WO |
WO-03059425 | Jul 2003 | WO |
WO-03047603 | Oct 2003 | WO |
WO-02085417 | Dec 2003 | WO |
WO-2005070035 | Aug 2005 | WO |
WO-2005070035 | Dec 2005 | WO |
WO-2005113046 | Dec 2005 | WO |
WO-2005113046 | Mar 2007 | WO |
WO-2009009540 | Jan 2009 | WO |
WO-2009035596 | Apr 2009 | WO |
WO-2010065616 | Jun 2010 | WO |
WO-2010090509 | Aug 2010 | WO |
WO-2013036540 | Mar 2013 | WO |
WO-2013090730 | Jun 2013 | WO |
WO-2015035315 | Mar 2015 | WO |
WO-2015035315 | May 2015 | WO |
WO-2016138045 | Sep 2016 | WO |
Entry |
---|
“EESR for EP18181995 dated Oct. 25, 2018”. |
European search report and opinion dated Oct. 13, 2010 for EP Application No. EP 05712159.2. |
European search report and search opinion dated Jun. 1, 2012 for EP Application No. 09831036.0. |
European Search Report dated May 11, 2017 for EP Application No. 14842468.2. |
“International search report and written opinion dated Apr. 2, 2015 for PCT/US2014/054579.” |
International search report and written opinion dated May 6, 2016 for PCT/US2016/019202. |
International search report dated May 3, 2010 for PCT/US2009/066380. |
International search report dated Sep. 8, 2005 for PCT/US2005/002600. |
Notice of allowance dated Jan. 21, 2015 for U.S. Appl. No. 13/780,866. |
Notice of Allowance dated Apr. 11, 2017 for U.S. Appl. No. 14/657,408. |
Notice of allowance dated Jul. 23, 2012 for U.S. Appl. No. 12/269,009. |
Notice of Allowance dated Aug. 23, 2017 for U.S. Appl. No. 14/479,128. |
Notice of allowance dated Oct. 31, 2011 for U.S. Appl. No. 10/587,103. |
Notice of allowance dated Nov. 23, 2012 for U.S. Appl. No. 13/326,101. |
Office Action dated Mar. 17, 2017 for U.S. Appl. No. 14/479,128. |
Office Action dated Mar. 26, 2015 for U.S. Appl. No. 13/255,867. |
Office action dated Apr. 10, 2012 for U.S. Appl. No. 13/326,101. |
Office Action dated May 30, 2017 for U.S. Appl. No. 13/255,867. |
Office action dated Jul. 3, 2014 for U.S. Appl. No. 13/780,866. |
Office Action dated Aug. 11, 2016 for U.S. Appl. No. 13/255,867. |
Office action dated Sep. 14, 2012 for U.S. Appl. No. 13/326,101. |
Office Action dated Sep. 15, 2016 for U.S. Appl. No. 14/657,408. |
Office Action dated Sep. 17, 2015 for U.S. Appl. No. 13/255,867. |
Office Action dated Oct. 11, 2016 for U.S. Appl. No. 14/479,128. |
Office Action dated Sep. 15, 2017 for U.S. Appl. No. 14/479,128. |
POGONIP in Pittsburg air. Weather man there says it's death from frozen fog. New York Times. Jan. 12, 1910. |
U.S. Appl. No. 14/479,128 Office Action dated May 15, 2018. |
Office action dated Mar. 3, 2020 for U.S. Appl. No. 15/575,306. |
Office action dated Mar. 9, 2020 for U.S. Appl. No. 15/610,291. |
Number | Date | Country | |
---|---|---|---|
20190175866 A1 | Jun 2019 | US |
Number | Date | Country | |
---|---|---|---|
61875093 | Sep 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14479128 | Sep 2014 | US |
Child | 16273941 | US |